The Global Acute Dystonia Market is estimated to be valued at US$ 120.7 million in 2024 and is expected to exhibit a CAGR of 3.2% over the forecast period 2024 to 2031.
The global acute dystonia market is mainly driven by the increasing prevalence of acute dystonia disorders such as cerebral palsy, encephalitis, Parkinson’s disease, post-procedural conditions and drug induced acute dystonia. Acute dystonia includes involuntary muscle contractions causing abnormal movements and postures. Drugs used for treating acute dystonia include anticholinergic agents, benzodiazepines and anti-convulsants which provide relief from dystonic movements. As per estimates, over 200,000 people in the US are affected by acute dystonia each year. The rising prevalence of acute dystonia disorders, increasing research and development activities by pharmaceutical players and entry of generic drugs are some of the factors fueling the growth of this market.
The Global Acute Dystonia Market is estimated to be valued at US$ 120.7 million in 2024 and is expected to exhibit a CAGR of 3.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global acute dystonia market are Fresenius Kabi, Amar Healthcare, Johnson & Johnson, PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd. These players are focusing on expanding their generic drug portfolio and developing novel drug delivery systems for long-acting drugs to treat acute dystonia more effectively.
The Global acute dystonia Market Growth offers lucrative growth opportunities including expanding awareness programs about dystonia, rising adoption of advanced diagnostic procedures and collaboration with hospitals and healthcare facilities. Key market players are investing heavily in R&D to develop biologics and introduce new treatment protocols to target unmet needs in acute dystonia management.
North America holds the largest share in the global acute dystonia market due to high healthcare expenditure, availability of advanced treatment facilities and presence of major players. However, Asia Pacific is anticipated to offer highest growth opportunities owing to increasing population suffering from acute dystonia, rising medical tourism and improving healthcare infrastructure.
Market Drivers
The primary drivers for the acute dystonia market include rising prevalence of conditions that trigger acute dystonia such as cerebral palsy, head injury, brain surgery or viral encephalitis. Drugs causing drug-induced acute dystonia like antipsychotics, antiemetics and dopamine receptor blockers are also contributing to market growth. Growing awareness about dystonia care and availability of advanced therapeutic options are further fueling the demand.
Market Restraints
However, high costs of dystonia drugs, fewer treatment guidelines and lack of experienced healthcare professionals in developing nations are some of the major factors restricting the growth of global acute dystonia market. Strong pipeline competitors and generic erosion of certain branded drugs after patent expiration also poses challenges. Lack of approved drugs for certain types of dystonia further limits the market potential.
Segment Analysis
The global acute dystonia market is dominated by the anti-cholinergic segment which accounts for nearly 50% of the overall market share. Anti-cholinergics such as trihexyphenidyl are considered as first line treatment for acute dystonia owing to their high efficacy and wide availability in both generic and branded formulations. Easy administration through oral route further drives the growth of this segment. The benzodiazepines segment is the second largest segment in the acute dystonia market due to benefits such as rapid onset of action and fewer drug interactions. Drugs such as diazepam and lorazepam are commonly used for treatment of dystonic reactions induced by neuroleptics.
Global Analysis
Regionally, North America dominates the global acute dystonia market and is expected to continue its dominance during the forecast period. High healthcare expenditure, presence of major players, increasing research on neurological disorders are some factors contributing to North America's large share. Europe holds the second position fueled by rising dyskinesia cases induced by anti-dopaminergic therapy. However, Asia Pacific is estimated to grow at the fastest rate owing to increasing awareness, growing geriatric population and healthcare infrastructure development in emerging nations like India and China. Increased focus of major pharmaceutical companies on tapping opportunities in Asia Pacific also supports market growth in the region.
Get more insights on this topic: Global Acute Dystonia Market
Comments
0 comment